Project Details
Description
PROJECT SUMMARY
Oncolytic virotherapy is a two-stage therapy. In the oncolytic phase (short-lived) the infection spreads in the
tumor, killing infected cells and inflaming the microenvironment. In the immune phase (prolonged) priming and
amplification of tumor-specific cytotoxic T cells (CTLs) by inflammatory mediators and phagocytosed debris
from dead or dying tumor cells leads to killing of uninfected tumor cells. VSV-IFNβ-NIS is a fast-replicating
oncolytic Vesicular Stomatitis Virus (VSV) that causes inflammatory tumor cell killing. During the first Myeloma
SPORE funding period, we launched an investigator initiated first-in-human study of single dose, single agent
intravenous (IV) VSV-IFNβ-NIS in patients with hematological malignancies. There is good tolerability and
encouraging signs of antitumor activity. Extensive correlative analyses have been conducted to characterize
the kinetics of the antitumor immune responses, and their relationship to patient-specific baseline parameters.
During the second Myeloma SPORE funding period we seek to maximize the potency of intravenous
VSVIFNβ-NIS therapy by combining (i) repeat virus administration, (ii) early suppression of the antiviral
immune response, and (iii) late boosting of antimyeloma T cells by using a combination of immune suppression
and immune activating regimens with the overall goal to achieve a durable response using VSV virotherapy in
patients with multiple myeloma.
Status | Finished |
---|---|
Effective start/end date | 9/15/21 → 8/31/23 |
Funding
- National Cancer Institute: $296,745.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.